A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis

A Roberto¹
MT Greco²
L Legramandi³
F Galli³
M Galli⁴
O Corli¹

¹Pain and Palliative Care Research Unit, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; ²Department of Clinical Sciences and Community, University of Milan, Milan, Italy; ³Methodology for Clinical Research Laboratory, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; ⁴Scientific Medical Communication srl, Novara, Italy

Background: Opioids are the most important pharmacological treatment for moderate-to-severe cancer pain, but side effects limit their use. Transdermal fentanyl (TDF) and oral prolonged-release oxycodone-naloxone (OXN-PR) are effective in controlling chronic pain, with less constipation compared to other opioids. However, TDF and OXN-PR have never been directly compared.

Patients and methods: Cancer patients with moderate-to-severe chronic pain were consecutively enrolled in two prospective 28-day trials, received either TDF or OXN-PR, and were assessed at baseline and after 7, 14, 21, and 28 days. The primary endpoint was 28-day analgesic response rate (average pain intensity decrease ≥30% from baseline). Other outcome measures included opioid daily dose changes over time; need for adjuvant analgesics; number of switches; premature discontinuation; presence and severity of constipation; and other adverse drug reactions. To compare the efficacy and the safety of TDF and OXN-PR, we used the propensity score analysis to adjust for heterogeneity between the two patient groups.

Results: Three hundred ten out of 336 patients originally treated (119 TDF and 191 OXN-PR) were included in the comparative analysis. The amount of responders was comparable after TDF (75.3%) and OXN-PR administration (75.1%, not significant [NS]). The final opioid daily dose expressed as morphine equivalent was 113.6 mg for TDF and 44.5 mg for OXN-PR (p < 0.0001). A daily opioid dose escalation >5% was less common after OXN-PR (19.3%) than after TDF administration (37.9%, p < 0.0001). Opioid switches and discontinuation were similar in both groups. Severe constipation in the two groups was comparable (32.6% after TDF vs 24.7% after OXN-PR, NS). Nausea, vomiting, and dry mouth were significantly less frequent in the OXN-PR group than in the TDF group.

Conclusion: Despite a similar analgesic activity in moderate-to-severe cancer pain, OXN-PR is characterized by lower daily dosages, less need for drug escalation, and fewer side effects compared to TDF.

Keywords: opioid induced constipation, oxycodone-naloxone, transdermal fentanyl, propensity score, analgesic efficacy, constipation

Background

The World Health Organization (WHO)¹ and recent international guidelines for the pharmacological treatment of cancer pain suggest that opioids are the best established therapy for moderate-to-severe cancer pain, recommending oral morphine, oxycodone, and hydromorphone as primary options for strong opioid therapy (Step III).²,³ Despite some variability in their responses, a recent study found comparable efficacy...
and tolerability profiles of morphine, oxycodone, and either transdermal fentanyl (TDF) or buprenorphine in cancer patients naïve to strong opioids.

However, burdensome side effects limit the compliance to opioids in the long term, because they often induce bowel dysfunction, including constipation, incomplete evacuation, hard dry stools, bloating, abdominal cramping, and gastric reflux. The European Association of Palliative Care (EAPC) and the European Society of Medical Oncology strongly recommend routine laxative prescriptions for prophylaxis and management of opioid-induced bowel dysfunction in advanced cancer patients receiving opioids.

To decrease the gastrointestinal adverse effects of opioids, oral prolonged-release oxycodone combined with naloxone (OXN-PR) in a 2:1 ratio was developed. The binding of oxycodone to the intestinal opioid receptors is strongly opposed by the opioid receptor antagonist naloxone, due to the higher receptor affinity of the latter. Conversely, the extensive hepatic first-pass metabolism limits the oral administered naloxone’s bioavailability, thus avoiding the interference with the central analgesic action of oxycodone.

In randomized controlled trials (RCTs) and postmarketing studies, OXN-PR has caused less opioid-induced bowel dysfunction than traditional opioids, particularly oral ones, with similar or even greater analgesic efficacy. Limited data, mainly from observational studies, are available on OXN-PR in cancer pain. and the efficacy and tolerability of OXN-PR and TDF have never been compared so far.

To partially cover this gap, we compared the analgesic efficacy and safety profiles of OXN-PR and TDF in strong opioid-naïve patients affected by moderate-to-severe chronic cancer pain. We used a propensity score (PS) analysis, a widely employed statistical method, to compare data recorded in nonrandomized treatment groups from different observational studies.

**Patients and methods**

**Study design, patients, and assessment**

Consecutive cancer patients with moderate-to-severe pain and naïve to WHO-Step III opioids were enrolled in two prospective 28-day multicenter studies (NCT01809106 and NCT02293785) and received either TDF or OXN-PR. The two trials were carried out sequentially in Italy in 2011–2015 and had identical clinical settings, eligibility criteria, efficacy and tolerability endpoints, and outcome measures.

Briefly, patients were included in the two studies if they met the following eligibility criteria: age >18 years; locally advanced or metastatic tumor (with the exclusion of cerebral tumors and leukemia given their different pain mechanisms); persistent moderate-to-severe cancer pain (average pain intensity [API] in the last 24 h ≥4 points on a 0–10 numerical rating scale, where 0 indicates no pain and 10 the worst imaginable pain) requiring WHO-Step III opioids and suitable for treatment with OXN-PR or TDF; no previous treatment with WHO-Step III opioids (strong opioid naïve). Pregnant women, patients with preexisting renal failure, history of alcohol or drug abuse, cognitive impairment, and those who received chemo- or radiotherapy in the 7 days before the observation period or any nonpharmacological analgesics were excluded.

Patients were evaluated at baseline (T0) and at 7, 14, 21, and 28 days thereafter, and they were closely monitored through a careful titration of their analgesic treatment. Demographic information (age and sex) and details of clinical history (primary tumor site, sites of metastases, previous treatments for pain, previous and ongoing cancer treatments, concomitant diseases, and Karnofsky Performance Status) were recorded at T0. The following pain characteristics were assessed: API experienced in the previous 24 h; neuropathic pain, evaluated by the Douleur Neuropathique 4 [Neuropathic Pain 4] inventory, which consists of pain descriptors and bedside sensory examinations commonly used in the clinical practice and research; type of pain (nociceptive, neuropathic, mixed); and breakthrough pain (BTP) according to the Davies algorithm. Overall therapy under way at the beginning of the study and any new drugs scheduled during observation were also recorded.

The starting dose of TDF (12.5–25 µg/h) or OXN-PR (5/2.5–20/10 mg/day) was determined by a pain physician according to the EAPC recommendations and by considering each patient’s needs and previous analgesic therapy. During follow-up, physicians were allowed to adjust the starting dose to better control the pain. The adjustments could include not only changes in the dose but also addition of another opioid or adjuvant drug(s), either discontinuation of the original therapeutic strategy or switching to another strong opioid in case of unsatisfactory analgesia, or intolerable adverse drug reactions (ADRs).

**Outcome measures**

During each visit, the analgesic efficacy was determined on the basis of the API. Other measures included around-the-clock (ATC) opioid daily doses (expressed as oral morphine-equivalent daily dose, mg); changes of analgesic therapy, type(s) and dose(s) of extra opioids or adjuvant drugs; opioid switch or discontinuation.
Safety was assessed at any visit using a self-administered
questionnaire to record any side effect that appeared or
changed in intensity or frequency after the TDF or OXN-PR
administration. ADR severity was measured by means of a
four-point verbal rating scale (no, light, moderate, severe),
according to the Therapy Impact Questionnaire.18

Based on the existing data on the clinically meaningful
changes of this parameter,4,19,20 we considered as “Responders”
those patients who obtained an average pain intensity
difference (APID) ≥30% by comparing the first and last visit.
The proportion of responders (for both TDF and OXN-PR)
was considered as the primary efficacy endpoint.

To evaluate the overall risk–benefit profile of TDF and
OXN-PR, an additional co-primary composite efficacy
and tolerability endpoint (clinical success) was used and
it included the simultaneous presence of APID ≥50% and
absence of moderate or severe ADRs in the study period,
indicating a worthwhile analgesic benefit.

The secondary endpoints included 1) opioid dose
increases after the observation time; 2) the proportion of
patients requiring a mean increase of >5% in the opioid
daily dose according to the Opioid Escalation Index% (OEI%),21
defined as follows:

\[
\text{OEI}\% = \frac{(\text{Final opioid daily dose} - \text{Opioid daily dose T0})}{\text{Opioid daily dose T0}} \times \frac{100}{\text{Number of days}}
\]

3) the proportion of patients requiring a switch to another
opioid because of inefficacy or toxicity; 4) the proportion
of patients needing supplementary doses of opioids or
adjuvant analgesic drugs to optimize the ATC therapy; 5)
the proportion of patients discontinuing the opioid for pain
treatment-related reasons; and 6) the proportion of patients
with severe constipation.

Statistical analysis
In the descriptive analyses, absolute frequency was used
for categorical variables, and central trend and dispersion
measurements (mean, standard deviations) were used for
quantitative continuous variables. Continuous/ordinal vari-
able were checked for normality of data distribution by
Shapiro–Wilk test and were then compared by running
either one-way analysis of variance or nonparametric tests.
Chi-square or Fisher’s exact tests were used for categorical
variables. Linear interpolation was used to impute intermittent
missing scores; the last observation carried forward was used
to impute missing values in the event of early discontinuation.

To compare the efficacy and safety of TDF and OXN-
PR, we used a PS analysis to adjust for differences between
the two patient groups. PS aims to allocate each patient the
conditional probability of receiving one of the treatments
available in an observational study, with a function of con-
 founding variables that influence the choice of treatment by a
physician.22,23 The probability of being assigned to TDF
or OXN-PR was determined using a multivariable logistic
regression model that included the following explanatory
variables: age, sex, metastasis, API, Karnofsky Performance
Status, previous anticancer therapy, previous WHO-II
therapy, and constipation at baseline.

The PS score was also included in the generalized lin-
ear outcome model as a covariate to allow the comparison
between the two samples.

A p-value of <0.05 was considered as statistically signifi-
cant. All statistical analyses were performed with SAS 9.2
statistical software (SAS Institute, Cary, NC, USA).

Ethics approval and consent to participate
For both studies and in each participating center, the study
protocol obtained the ethical approval and patients pro-
vided a written informed consent before any study-related
activities were carried out (for details see Supplementary
material).

Results
Three hundred thirty-six patients were originally enrolled in
the two studies and treated for moderate-to-severe cancer pain
with either TDF or OXN-PR. However, only 310 patients (119
TDF and 191 OXN-PR) were included in the final compara-
tive analysis by PS (Figure 1).

Table 1 shows the baseline clinical characteristics accord-
ing to the different treatments. The most common sites of can-
cer were the respiratory, digestive, and genitourinary systems.
Over 80% of patients in each group reported metastases at
baseline and over 70% received anticancer therapy. Almost
three quarters of the TDF patients (70.5%) and less than half
of the OXN-PR patients (47.1%; p=0.0016) switched from
a weak opioid to a new analgesic. The API at entry was 6.2
in both groups, with a high prevalence of nociceptive pain
(>80%) compared to neuropathic or mixed pain. Almost a
half of the patients reported episodes of BTP at entry.

The results about study adherence are reported in Table 2:
over the 28-day follow-up, 52 (16.8%) patients prematurely
either withdrew from the treatment or were withdrawn from
the observation, and 24 (7.7%) patients were lost at follow-up.
The remaining 234 (75.4%) patients continued with the same analgesic treatment up to the end of the observation.

**Analgesic efficacy**

Clinical measures and endpoints are reported in Table 3. The proportions of responders were not significantly different after the administration of either TDF or OXN-PR (75.3% and 82.9%, respectively; \(p = 0.11\)). In both groups, API decreased from baseline to day 28 (Figure 2): from 6.2 ± 1.5 to 2.4 ± 2.0 in patients administered with TDF and from 6.2 ± 1.1 to 2.6 ± 1.7 in patients administered with OXN-PR (difference not significant).

Significant differences in opioid daily doses were recorded between the two groups at baseline (TDF: 53.0 mg; OXN-PR: 25.4 mg; \(p < 0.001\)). This difference increased during the observation (Figure 3): after 28 days, the opioid daily dose was 113.6 mg in patients treated with TDF, and 44.5 mg in patients treated with OXN-PR (\(p < 0.0001\)). Thus, an opioid daily dose escalation >5% was less common after OXN-PR (19.3% vs 37.9% after TDS, \(p < 0.0001\)) compared to TDF. At the end of the study, the rates of clinical success after TDF and OXN-PR were not significantly different (27.8% and 36.5%, respectively; \(p = 0.10\)).

No significant differences were found between TDF and OXN-PR regarding the proportions of patients who required either adjuvant drugs or additional opioids, or switched to other analgesics during the study period (Table 3).

**Tolerability and safety**

The types and severity of the ADRs recorded during the study in TDF and OXN-PR patients are reported in Table 4. Nausea, vomiting, and dry mouth were more common in TDF patients compared to OXN-PR ones. Severe constipation was comparable in the two groups (32.6% after TDF administration vs 24.7% after OXN-PR administration, not significant [NS]).

**Discussion**

This is the first study comparing the efficacy and safety of TDF and OXN-PR in cancer patients with moderate-to-severe pain. TDF is a strong opioid usually administered to patients with stable opioid requirements and suggested as an effective alternative to oral opioids for some patients (i.e., those unable
to swallow), according to international recommendations.2,6 By combining the opioid agonist–antagonist oxycodone and naloxone, OXN-PR is aimed at relieving pain and limiting opioid-induced constipation.

In the absence of interventional studies, these analyses allow comparing the analgesic efficacy and safety of TDF and OXN-PR. We analyzed data collected in two studies recently performed by our group and aimed at evaluating the characteristics of different opioids commonly used in cancer patients. To reduce the effects of confounding factors and to account for systematic differences in baseline characteristics between TDF and OXN-PR subjects, we applied the PS, an alternative statistical method previously used to compare the analgesic effectiveness between opioids in cancer patients.12,13

In 28 days of treatment, pain intensity decreased about 60% in both groups. A previous RCT showed that TDF and oxycodone (not in combination with naloxone) had equivalent analgesic effects in chronic cancer pain.15 The present analysis indicates that OXN-PR achieves comparable analgesic efficacy of TDF. Additionally, as previously mentioned, we considered as responders the patients who achieved a decrease of 30% or more of pain intensity from baseline to final visit, based on the Farrar criterion.19,24–27 Although the difference was not significant, by testing the primary efficacy endpoint of this analysis we found that the proportion of responders was slightly higher after OXN-PR compared to TDF administration.

The final to basal pain intensity difference and the positive response rate provided different information on the analgesic effect. In clinical studies, the results are mainly driven by the whole population’s mean values for specified outcomes and end points. The former method offers a general picture of the efficacy of a given treatment but does not allow to distinguish good from bad responses. A poor analgesic effect is a primary issue in clinical practice and a lack of response is

### Table 1 Main baseline demographic and clinical characteristics of the study population

<table>
<thead>
<tr>
<th>Main characteristics</th>
<th>Transdermal fentanyl (N=119)</th>
<th>PR oxycodone-naloxone (N=191)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>67.8 (10.7)</td>
<td>68.7 (9.8)</td>
</tr>
<tr>
<td>Female</td>
<td>53 (44.5%)</td>
<td>83 (43.5%)</td>
</tr>
<tr>
<td>Primary site of tumor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory system</td>
<td>34 (28.6%)</td>
<td>76 (39.8%)</td>
</tr>
<tr>
<td>Digestive system</td>
<td>27 (22.7%)</td>
<td>50 (26.2%)</td>
</tr>
<tr>
<td>Genitourinary system</td>
<td>24 (20.2%)</td>
<td>32 (16.8%)</td>
</tr>
<tr>
<td>Breast</td>
<td>10 (8.4%)</td>
<td>10 (5.2%)</td>
</tr>
<tr>
<td>Head, neck</td>
<td>12 (10.1%)</td>
<td>10 (5.2%)</td>
</tr>
<tr>
<td>Others</td>
<td>12 (10.1%)</td>
<td>13 (6.8%)</td>
</tr>
<tr>
<td>Metastases</td>
<td>99 (83.2%)</td>
<td>160 (83.8%)</td>
</tr>
<tr>
<td>Previous anticancer therapy</td>
<td>91 (76.5%)</td>
<td>134 (70.2%)</td>
</tr>
<tr>
<td>Surgery</td>
<td>55 (46.5%)</td>
<td>70 (52.2%)</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>70 (67.9%)</td>
<td>107 (79.9%)</td>
</tr>
<tr>
<td>Biologic medical products</td>
<td>17 (15.7%)</td>
<td>21 (15.7%)</td>
</tr>
<tr>
<td>Hormone therapy</td>
<td>12 (13.2%)</td>
<td>17 (12.7%)</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>35 (38.5%)</td>
<td>48 (35.8%)</td>
</tr>
<tr>
<td>Karnofsky Performance Status</td>
<td>67.4 (17.3)</td>
<td>66.3 (16.5)</td>
</tr>
<tr>
<td>Previous pain therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No therapy (WHO-Step 0)</td>
<td>13 (11.1%)</td>
<td>26 (13.6%)</td>
</tr>
<tr>
<td>Non-opioids (WHO-Step I)</td>
<td>21 (17.8%)</td>
<td>75 (39.3%)</td>
</tr>
<tr>
<td>Weak opioids (WHO-Step II)</td>
<td>84 (70.5%)</td>
<td>90 (47.1%)</td>
</tr>
<tr>
<td>Adjuvant pain therapies</td>
<td>54 (45.4%)</td>
<td>92 (48.2%)</td>
</tr>
<tr>
<td>Steroids</td>
<td>32 (26.3%)</td>
<td>64 (69.6%)</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>9 (16.7%)</td>
<td>16 (17.4%)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>6 (11.1%)</td>
<td>14 (15.2%)</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>7 (13.0%)</td>
<td>10 (10.9%)</td>
</tr>
<tr>
<td>Other</td>
<td>8 (14.8%)</td>
<td>10 (10.9%)</td>
</tr>
<tr>
<td>Pain duration (months)</td>
<td>3.2 (4.5)</td>
<td>3.3 (3.7)</td>
</tr>
<tr>
<td>Average pain intensity, NRS</td>
<td>6.2 (1.5)</td>
<td>6.2 (1.1)</td>
</tr>
<tr>
<td>Type of pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only nociceptive</td>
<td>102 (85.7%)</td>
<td>155 (81.2%)</td>
</tr>
<tr>
<td>Only neuropathic</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mixed</td>
<td>17 (14.3%)</td>
<td>36 (18.8%)</td>
</tr>
<tr>
<td>Breakthrough pain</td>
<td>55 (46.2%)</td>
<td>82 (42.9%)</td>
</tr>
<tr>
<td>Constipation</td>
<td>31 (26.1%)</td>
<td>74 (38.7%)</td>
</tr>
</tbody>
</table>

**Note:** Values are mean (± standard deviation) or number of patients (%).

**Abbreviations:** NRS, numerical rating scale; PR, prolonged release; WHO, World Health Organization.

### Table 2 Study adherence

<table>
<thead>
<tr>
<th></th>
<th>Transdermal fentanyl (N=119), n (%)</th>
<th>PR oxycodone-naloxone (N=191), n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed the 28-day study</td>
<td>87 (73.1)</td>
<td>147 (76.9)</td>
</tr>
<tr>
<td>Premature treatment</td>
<td>27 (22.6)</td>
<td>25 (13.1)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noncompliance</td>
<td>1 (3.7)</td>
<td>3 (12.0)</td>
</tr>
<tr>
<td>Refusal</td>
<td>0 (0)</td>
<td>1 (4.0)</td>
</tr>
<tr>
<td>Death</td>
<td>10 (37.0)</td>
<td>1 (4.0)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (14.8)</td>
<td>2 (8.0)</td>
</tr>
<tr>
<td>Inadequate analgesia</td>
<td>8 (29.6)</td>
<td>7 (28.0)</td>
</tr>
<tr>
<td>Severe ADRs</td>
<td>4 (14.8)</td>
<td>4 (16.0)</td>
</tr>
<tr>
<td>Inadequate analgesia and</td>
<td>0 (0)</td>
<td>1 (4.0)</td>
</tr>
<tr>
<td>severe ADRs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difficulty swallowing</td>
<td>0 (0.0)</td>
<td>6 (24.0)</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>5 (4.2)</td>
<td>19 (9.9)</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADRs, adverse drug reactions; PR, prolonged release.
### Table 3 Clinical measures and end points

<table>
<thead>
<tr>
<th>Clinical measures and end points</th>
<th>Transdermal fentanyl (N=119)</th>
<th>Oral oxycodone-naloxone (N=191)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responders</td>
<td>75.3% (3.7)</td>
<td>82.9% (2.9)</td>
<td>0.11</td>
</tr>
<tr>
<td>Clinical success</td>
<td>27.8% (4.4)</td>
<td>36.5% (3.4)</td>
<td>0.12</td>
</tr>
<tr>
<td>Starting opioid dose (mg/day)†</td>
<td>53.0 (1.3)</td>
<td>25.4 (1.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Final dose (mg/day)†</td>
<td>113.6 (4.9)</td>
<td>44.5 (3.9)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mean dose increase†</td>
<td>2.5 (1.8)</td>
<td>0.4 (1.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>OEI &gt;5%†</td>
<td>37.9% (4.1)</td>
<td>19.3% (3.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Patients requiring additional opioids</td>
<td>37.1% (4.4)</td>
<td>28.2% (3.4)</td>
<td>0.12</td>
</tr>
<tr>
<td>Patients requiring adjuvant drugs</td>
<td>83.7% (3.5)</td>
<td>82.4% (2.8)</td>
<td>0.78</td>
</tr>
<tr>
<td>Switches</td>
<td>14.1% (3.1)</td>
<td>10.6% (2.4)</td>
<td>0.37</td>
</tr>
<tr>
<td>Premature discontinuations due to ADRs</td>
<td>2.8% (1.2)</td>
<td>0.9% (0.9)</td>
<td>0.22</td>
</tr>
<tr>
<td>Severe constipation</td>
<td>32.6% (4.2)</td>
<td>24.7% (3.3)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Notes: Values are percentage or number (standard error); †around-the-clock daily doses (as oral morphine-equivalent daily dose).

Abbreviations: ADRs, adverse drug reactions; OEI, opioid escalation index.

#### Figure 2
Mean pain intensity score (11-point numerical rating scale) throughout observation after transdermal fentanyl and prolonged-release oxycodone-naloxone.

**Abbreviation:** OXN, oxycodone-naloxone.

#### Figure 3
Transdermal fentanyl and prolonged-release oxycodone-naloxone daily dosages (expressed in oral morphine-equivalent daily dose).

**Abbreviations:** OMEDD, oral morphine-equivalent daily dose; OXN, oxycodone-naloxone.
Itching
Breathlessness
Dysuria
Gastralgia
Muscle spasm/myoclonus
Hallucinations
Dry mouth
Constipation
Vomiting
Nausea
Confusion
Drowsiness

submit your manuscript
Journal of Pain Research  2017:10

opioids in cancer patients. They found that nonresponders aimed at comparing both efficacy and safety of four strong TDF and OXN-PR groups, respectively. Nonresponders amounted to 24.7% and 17.1% in the TDF and OXN-PR groups, with reporting pain intensity reduction <30% being considered a problem that needs to be understood and solved. Patients reporting pain intensity reduction <30% were considered nonresponders. They amounted to 24.7% and 17.1% in the TDF and OXN-PR groups, respectively.

These data confirm the results of a recent RCT study aimed at comparing both efficacy and safety of four strong opioids in cancer patients. They found that nonresponders ranged from 20% to 25% and that this variability depended on the administered drug. Noteworthy, nonresponders are by definition poorly susceptible to the action of opioids and this condition leads to a compensating increase of dose over time.

We observed a higher starting dose and a greater dose increase across the observation time in patients treated with TDF. The first might depend on frequent previous therapies with weak opioids in this group that quite likely induced higher doses requirement when starting the WHO-Step III. Independently from these basal conditions, we found an increase of 120% in the doses administered to the TDF group while the increase of the doses in the OXN-PR group reached 80%. This difference was confirmed by the OER% >5, significantly higher in TDF compared to OXN-PR patients.

Different degrees of dose escalation over time can generally be attributed to dissimilar tendencies to develop tolerance. Even if a comparative clinical study on the onset of tolerance to different opioids has not yet been performed, the degrees of tolerance for TDF and oxycodone have already been reported.

The prevalence of ADRs was substantially comparable after TDF and OXN-PR, except for nausea, vomiting, and dry mouth, which were more frequent among TDF recipients. A lower prevalence of nausea and vomiting after OXN-PR was also reported in other studies and a possible explanation might be that the opioid antagonist naloxone acts at the gastric level through the same mechanism as in limiting bowel dysfunction, thus reducing the development of nausea and vomiting. Constipation is a frequent problem, occurring in more than 40% of the patients treated with opioids. In previous studies, TDF was associated with less constipation than oral opioids. In the present analysis, the number of patients complaining of constipation was similar between TDF and OXN-PR.

Despite the notable aspects being addressed by the present analysis, we acknowledge that this study has several inherent limitations because of the method used to control for the imbalance between comparison groups. The assumption that high variance was considered in the model used to estimate the PS should be properly demonstrated. To optimize the PS, variables were selected by considering evidences in the literature and expert recommendations. Unlike randomization, PS analysis can only remove overt (known) bias, while hidden (unmeasured) biases remain. Therefore, the results generated using PS analysis must be carefully interpreted. The validity of the results depends on the quality and the quantity of information about the efficacy and safety of the evaluated treatments. The sample population characteristics are also important: PS analysis allows partial extrapolations to different patient groups and settings, with different distribution in the covariates used to generate the score. Different considerations arose from these results. First, by acknowledging the limits of the PS analysis, the problem of the generalizability of the results (external validity) becomes central;
second, there is a need to carefully take into account additional important determinants, which are involved in the physicians’ and patients’ decisions about whether or not to prescribe and use a treatment. However, despite its inherent limitations, the PS model may improve the understandings of the real value of results from observational studies. To date, only one RCT has compared the efficacy and safety of oxycodone-PR and OXN-PR in cancer pain, by involving an extremely selected cohort of patients with controlled pain and opioid-induced constipation at baseline. Future efforts should be aimed at comparing opioids in unselected patients with cancer by taking advantage of RCTs.

**Conclusion**

We analyzed patients affected by moderate-to-severe cancer pain and treated with either TDF or OXN-PR. Our results showed that the two opioids induced comparable analgesic efficacy, despite markedly lower daily dosages and less need for drug escalation in case of OXN-PR administration, thus highlighting less mid-term opioid tolerance with the agonist–antagonist combination. Nausea and vomiting were also reduced after OXN-PR, while constipation was comparable for the two opioids.

**Acknowledgments**

This study was completed independently, and the authors were the sole persons involved in the study design, data collection, and analysis, decision to publish, and preparation of the manuscript.

**Disclosure**

Dr. M. Galli was the scientific director of Mundipharma Pharmaceuticals until January 2017. Other authors report no conflicts of interest in this work.

**References**


Supplementary material

List of ethics committees for each participating center in both studies

**CERP study (NCT01809106) – 44 centers**

1. Comitato Etico Per La Sperimentazione Clinica Dei Farmaci Della Ausl Di Pescara – Pescara
2. Comitato Etico Dell’universita’ Degli Studi Gabriele D’annunzio E Della Asl 2 Lancianovasto-Chieti – Chieti
3. Comitato Etico Dell’a. O. Bianchi-Melacrino-Morelli – Reggio Calabria
4. Comitato Etico Dell’Irccs Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale – Naples
5. Comitato Etico Dell’A. O. V. Monaldi – Naples
6. Comitato Etico Dell’A. O. Antonio Cardarelli – Naples
7. Comitato Etico Indipendente Dell’A. O. U. Policlinico S. Orsola-Malpighi – Bologna
8. Comitato Etico Della Provincia Di Modena – Modena
9. Comitato Etico Unico Per La Provincia Di Parma – Parma
10. Comitato Etico Provinciale Di Reggio Emilia – Reggio Emilia
11. Comitato Etico Della Ausl Di Piacenza – Piacenza
12. Comitato Etico Di Area Vasta Romagna E Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori Di Meldola – Meldola
13. Comitato Etico Dell’Azienda Policlinico Umberto I – Rome
14. Comitato Etico Indipendente Fondazione Ptv Policlinico Tor Vergata – Rome
15. Comitato Etico Dell’ausl Di Viterbo – Viterbo
16. Comitato Etico Dell’asl 3 Genovese – Genoa
17. Comitato Etico Dell’Ente Ospedaliero Ospedali Galliera – Genoa
18. Comitato Etico Dell’A. O. Universitaria S. Martino – Genoa
19. Comitato Etico Fondazione S. Maugeri – Pavia
20. Comitato Etico Dell’A.O. Ospedale Di Circolo – Busto Arsizio
22. Comitato Etico Istituti Clinici Di Perfezionamento – Milan
23. Comitato Indipendente Di Etica Dell’a.O. Carlo Poma – Mantova
25. Comitato Etico Interzionale Della Asur Zona Territoriale 8 Di Civitanova Marche E Zona Territoriale 9 – Macerata
26. Comitato Etico Dell’azienda Sanitaria Provinciale – Trapani
28. Comitato Etico Della Asl To/2 Di Torino – Gradenigo
29. Comitato Etico Dell’A. O. U. Policlinico-Vittorio Emanuele – Catania
30. Comitato Etico Lazio 2 – Sora
31. Comitato Etico Dell’Irccs Multimedica – Sesto San Giovanni
32. Comitato Etico Interzionale Della Asur Zona Territoriale 8 Di Civitanova Marche E Zona Territoriale 9 – Macerata
33. Comitato Etico Asl Di Cagliari – Cagliari
34. Comitato Etico Di Bioetica Ospedale San Pietro – Roma
35. Comitato Etico Indipendente Istituto Nazionale Dei Tumori – Milano
36. Comitato Etico Fondazione S. Raffaele Del Monte Tabor – Milano
37. Comitato Etico A.O. S. Paolo – Milano
38. Comitato Etico Dell’A. O. Della Valtellina E Della Valchiavenna – Morbegno
39. Comitato Etico Per La Sperimentazione Clinica – Mirano
40. Comitato Etico Milano Area B – Milan
Great study (NCT02293785) – 14 centers
1. Comitato Etico Milano Area B – Milan (Coordinating Center)
2. Comitato Etico Dell’Ao Specialistica Dei Colli Monaldi-Cotugno-Cto – Naples
3. Comitato Etico Sapienza – Rome
4. Comitato Etico Per La Sperimentazione Clinica – Mirano
5. Comitato Etico Per Le Sperimentazioni Cliniche (Cesc) – Padua
6. Comitato Etico Azienda Usl Di Piacenza – Piacenza
7. Comitato Etico Ospedale San Raffaele – Milan
8. Comitato Etico Interaziendale Novara – Biella
9. Comitato Etico Indipendente Fondazione Ptv Policlinico Tor Vergata – Rome
10. Comitato Etico Regione Liguria – Genoa
11. Comitato Etico Indipendente, Cro Aviano – Aviano
12. Comitato Etico Palermo 2 – Trapani
13. Comitato Etico Lazio 1 – Rome